{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:nitroglycerin",
  "owner": "cardio",
  "kind": "drug",
  "slug": "nitroglycerin",
  "name": "Nitroglycerin",
  "aliases": [
    "Nitrostat",
    "Glyceryl trinitrate"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Nitroglycerin, sold for under-the-tongue use as Nitrostat, is a nitrate, a vasodilator (a medicine that widens blood vessels). The US label read, for Nitrostat sublingual tablets, lists the acute relief of an attack of angina pectoris, chest pain from coronary artery disease, and the acute prevention of an attack. The label says the principal action of nitroglycerin is relaxation of vascular smooth muscle. Other nitroglycerin products were not read.",
  "summary_technical": "RxNorm ingredient 4917 (synonym glyceryl trinitrate); UNII G59M7S0WS3. MeSH descriptor D005996 is Nitroglycerin. RxClass lists the FDA chemical class Nitrates and the established pharmacologic class Nitrate Vasodilator; the record is filed under the class page Nitrates on that evidence. The label read is the Viatris Specialty LLC label for Nitrostat, application NDA021134, effective 2023-02-15 in openFDA, the label the class page already uses. The plan row pointed at a generic label (ANDA089773); the single-ingredient brand label replaces it. Nitrostat labels from repackagers and other nitroglycerin products were not read. Statements are scoped to the sublingual tablet. This page records the label indication, the product form and the mechanism sentence only: no trial result and no dose is given.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-18",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "rxnorm",
      "value": "4917",
      "normalized_value": "4917",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "unii",
      "value": "G59M7S0WS3",
      "normalized_value": "G59M7S0WS3",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "mesh",
      "value": "D005996",
      "normalized_value": "D005996",
      "match": "exact",
      "version": "read 2026-11-18",
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "heart"
      ],
      "condition-area": [
        "coronary-and-vascular-disease"
      ]
    }
  },
  "payload": {
    "level": "substance",
    "mechanism": "The label says the principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle."
  },
  "content_digest": "7542d7ab1aa64524d07335226cbe094f1e39b8230fbb720bfc09d349a45a1bf4",
  "review": {
    "content_digest": "7542d7ab1aa64524d07335226cbe094f1e39b8230fbb720bfc09d349a45a1bf4",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-nitroglycerin-label-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:nitroglycerin",
      "category": "descriptive",
      "statement": "The US label of Nitrostat (nitroglycerin sublingual tablets, Viatris Specialty LLC, application NDA021134; the version dated 2023-02-15 in openFDA) describes the product as a stabilized sublingual compressed nitroglycerin tablet and a nitrate vasodilator. It lists the acute relief of an attack, or acute prophylaxis of an attack, of angina pectoris due to coronary artery disease.",
      "context": {
        "id": "cardio:ctx-fda-nitrostat-label-us",
        "label": "People with angina pectoris due to coronary artery disease, as described in the US label of Nitrostat sublingual tablets",
        "recipient": "unknown",
        "population": "Patients with angina pectoris due to coronary artery disease, for the acute relief or the acute prophylaxis of an attack, as the indications section of the label states. The label passages read do not state an age range.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Not stated in the label passages read",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Patients with angina pectoris due to coronary artery disease"
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label is for the sublingual tablet only; other nitroglycerin products were not read. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read.",
          "snapshot": {
            "id": "cardio:openfda-label-nitrostat-2026-11-18",
            "retrieved_at": "2026-11-18T20:11:52Z",
            "content_hash": "cae4d61c84fb7ab7ae29bb11fadbc657fd705f74cd61c6d6651902c24afdebbb",
            "source_effective_date": "2023-02-15",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-nitrostat",
            "source_type": "regulator",
            "title": "openFDA drug label record for Nitrostat (nitroglycerin sublingual tablets), Viatris Specialty LLC label: indication, description, pharmacodynamics",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%229a52da75-d0af-4237-96c0-0b12adfa8636%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 9a52da75-d0af-4237-96c0-0b12adfa8636 (manufacturer Viatris Specialty LLC, application NDA021134), returned on 2026-11-18. The label text is dated 2023-02-15 (effective_time). Other openFDA records of Nitrostat labels from repackagers, and labels of other nitrate products, exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k06-openfda-label-nitrostat.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read.",
          "snapshot": {
            "id": "cardio:openfda-label-nitrostat-2026-11-18",
            "retrieved_at": "2026-11-18T20:11:52Z",
            "content_hash": "cae4d61c84fb7ab7ae29bb11fadbc657fd705f74cd61c6d6651902c24afdebbb",
            "source_effective_date": "2023-02-15",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-nitrostat",
            "source_type": "regulator",
            "title": "openFDA drug label record for Nitrostat (nitroglycerin sublingual tablets), Viatris Specialty LLC label: indication, description, pharmacodynamics",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%229a52da75-d0af-4237-96c0-0b12adfa8636%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 9a52da75-d0af-4237-96c0-0b12adfa8636 (manufacturer Viatris Specialty LLC, application NDA021134), returned on 2026-11-18. The label text is dated 2023-02-15 (effective_time). Other openFDA records of Nitrostat labels from repackagers, and labels of other nitrate products, exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k06-openfda-label-nitrostat.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0]",
          "applicability_note": "Label passage quoted in the research quote table (NIT-LB-04, NIT-LB-05).",
          "snapshot": {
            "id": "cardio:openfda-label-nitrostat-2026-11-18",
            "retrieved_at": "2026-11-18T20:11:52Z",
            "content_hash": "cae4d61c84fb7ab7ae29bb11fadbc657fd705f74cd61c6d6651902c24afdebbb",
            "source_effective_date": "2023-02-15",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-nitrostat",
            "source_type": "regulator",
            "title": "openFDA drug label record for Nitrostat (nitroglycerin sublingual tablets), Viatris Specialty LLC label: indication, description, pharmacodynamics",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%229a52da75-d0af-4237-96c0-0b12adfa8636%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 9a52da75-d0af-4237-96c0-0b12adfa8636 (manufacturer Viatris Specialty LLC, application NDA021134), returned on 2026-11-18. The label text is dated 2023-02-15 (effective_time). Other openFDA records of Nitrostat labels from repackagers, and labels of other nitrate products, exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k06-openfda-label-nitrostat.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].description[0]",
          "applicability_note": "Label passage quoted in the research quote table (NIT-LB-06).",
          "snapshot": {
            "id": "cardio:openfda-label-nitrostat-2026-11-18",
            "retrieved_at": "2026-11-18T20:11:52Z",
            "content_hash": "cae4d61c84fb7ab7ae29bb11fadbc657fd705f74cd61c6d6651902c24afdebbb",
            "source_effective_date": "2023-02-15",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-nitrostat",
            "source_type": "regulator",
            "title": "openFDA drug label record for Nitrostat (nitroglycerin sublingual tablets), Viatris Specialty LLC label: indication, description, pharmacodynamics",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%229a52da75-d0af-4237-96c0-0b12adfa8636%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 9a52da75-d0af-4237-96c0-0b12adfa8636 (manufacturer Viatris Specialty LLC, application NDA021134), returned on 2026-11-18. The label text is dated 2023-02-15 (effective_time). Other openFDA records of Nitrostat labels from repackagers, and labels of other nitrate products, exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k06-openfda-label-nitrostat.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "42cfdf8954b3f49fb8ee0268ae70779d6f0c969da8138add68d96a85d2aea2f5",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-nitroglycerin-label-indications.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "subtype_of",
        "label": "Nitroglycerin is a nitrate vasodilator (FDA established pharmacologic class in RxClass)",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:nitrates",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-4917-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[2].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists the acute relief and acute prophylaxis of an attack of angina pectoris due to coronary artery disease as the indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:angina-pectoris",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-nitroglycerin-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": []
  },
  "page_path": "drugs/nitroglycerin/",
  "context_path": "api/v1/context/cardio--nitroglycerin.md"
}
